Skip to main content
CivicGate

S 1322
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

SALTS Act

To amend the Controlled Substances Act relating to controlled substance analogues.

Introduced Jul 18, 2013

Latest action (May 14, 2014) Committee on United States Senate Caucus on International Narcotics Control. Hearings held.

Referred to
United States Senate Caucus on International Narcotics Control Judiciary Committee
Policy area
Crime and Law Enforcement
Issues
Criminal Justice
Legislative subjects (3)
Drug, alcohol, tobacco useDrug trafficking and controlled substancesMarketing and advertising

Summary

This bill amends the Controlled Substances Act to establish clearer standards for determining when synthetic drug analogues—chemical variations of controlled drugs—are illegal. It provides specific factors courts can use to determine if an analogue was intended for human consumption, including how it is marketed and advertised, its price compared to similar drugs, and whether it was diverted from legitimate channels. The bill clarifies that just labeling a substance for non-human use is not enough to make it legal if evidence shows it was actually intended for consumption by injection, inhalation, or ingestion. This aims to address sales of synthetic drugs marketed under misleading labels or purposes.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
5 cosponsors

Actions (4)
  1. May 14, 2014 Committee on United States Senate Caucus on International Narcotics Control. Hearings held. · senate
  2. Sep 25, 2013 Committee on United States Senate Caucus on International Narcotics Control. Hearings held. · senate
  3. Jul 18, 2013 Read twice and referred to the Committee on the Judiciary. · senate
  4. Jul 18, 2013 Introduced in Senate

More bills on these subjects (8)

Other bills that carry the most legislative subjects in common with this one (topical discovery — distinct from the procedural related bills above).

  • HR 7757 — KIDS Act (shares 3 subjects)
  • HR 1654 — CUTS Act (shares 3 subjects)
  • HR 9770 — Continuing Appropriations Act, 2027 (shares 2 subjects)
  • SRES 704 — A resolution supporting the mission and goals of National Fentanyl Awareness Day in 2026, including increasing individual and public awareness of the impact of fake or counterfeit fentanyl pills on families and young people. (shares 2 subjects)
  • S 3618 — No Fentanyl on Social Media Act (shares 2 subjects)
  • HR 7148 — Consolidated Appropriations Act, 2026 (shares 2 subjects)
  • HR 7006 — Financial Services and General Government and National Security, Department of State, and Related Programs Appropriations Act, 2026 (shares 2 subjects)
  • HR 6259 — No Fentanyl on Social Media Act (shares 2 subjects)

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • S 1323 — Protecting Our Youth from Dangerous Synthetic Drugs Act of 2013 · Introduced May 14, 2014 · Cong. 113 74%
  • S 1383 — Drug Sentencing Reform Act of 2007 · Introduced Feb 12, 2008 · Cong. 110 66%
  • S 165 — Stopping Overdoses of Fentanyl Analogues Act · Introduced Jan 21, 2025 · Cong. 119 65%
  • S 289 — Youth Poisoning Protection Act · Passed Senate Aug 10, 2026 · Cong. 119 64%
  • S 2316 — Cooper Davis and Devin Norring Act · Introduced Jul 17, 2025 · Cong. 119 63%
  • S 242 — Pharmaceutical Market Access and Drug Safety Act of 2007 · Introduced Mar 7, 2007 · Cong. 110 61%

Text versions (1)
  • Introduced in Senate · Jul 18, 2013

Only one text version is on file, so there’s no earlier version to compare against yet.

Full text

IN THE SENATE OF THE UNITED STATES

July 18, 2013

Ms. Klobuchar (for herself, Mr. Graham, and Mrs. Feinstein) introduced the following bill; which was read twice and referred to the Committee on the Judiciary

A BILL

To amend the Controlled Substances Act relating to controlled substance analogues.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Synthetic Abuse and Labeling of Toxic Substances Act of 2013” or the “SALTS Act”.

SEC. 2. CONTROLLED SUBSTANCE ANALOGUES.

Section 203 of the Controlled Substances Act (21 U.S.C. 813) is amended—

(1) by striking “A controlled” and inserting “(a) In General.—A controlled”; and

(2) by adding at the end the following:

“(b) Determination.—In determining whether a controlled substance analogue was intended for human consumption under subsection (a), the following factors may be considered, along with any other relevant factors:

“(1) The marketing, advertising, and labeling of the substance.

“(2) The known efficacy or usefulness of the substance for the marketed, advertised or labeled purpose.

“(3) The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold.

“(4) The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance.

“(5) Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means.

“(c) Limitation.—For purposes of this section, evidence that a substance was not marketed, advertised, or labeled for human consumption, by itself, shall not be sufficient to establish that the substance was not intended for human consumption.”. <all>

Comments

Comments

Loading comments…